Do we need to test for isoniazid resistance? No conflict of interest Claudia Denkinger, MD PhD McGill University, Montreal Foundation for Innovative New.

Slides:



Advertisements
Similar presentations
DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Advertisements

Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
The Re- emerging Threat of TB Magnitude of the Problem Associated Factors & challenges Current strategies Aamod Asmita Dr. Bala Dr. Arun Dr. Samraj Nisha.
Trends in TB R&D investment: Where is funding most needed? Lindsey Wu Policy Analyst Policy Cures
1 |1 | Implementing HIV and TB Diagnostics in Resource Cape Town, South Africa, September 23 rd, 2014 New diagnostic technologies in development and target.
Introduction India has the highest burden of tuberculosis in the world, with an estimated 2 million cases annually, accounting for 1/5 th of global incidence.
A User-Friendly, Open-Source Tool to Project Impact and Costs of Diagnostic Tests for Tuberculosis David Dowdy, MD PhD June 6, 2013 Ctr for TB Research.
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
Access to TB Drugs and Diagnostics Gregg Gonsalves Open Society Foundations Division of the Epidemiology of Microbial Diseases, Yale School of Public Health.
Dr Susan Zimba –Tembo Professional Officer – WHO 1 st March 2013, Crest Golf Hotel.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
Monitoring and Evaluation Frameworks Kyiv, Ukraine May 23, 2006 MEASURE Evaluation.
Richard Kohler, MD TB Consultant, Indiana State Department of Health Division of Infectious Diseases Indiana University School of Medicine.
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
Monitoring and Evaluation Frameworks   What is an M&E Framework?   Why do we use M&E Frameworks?   How do we develop M&E Frameworks? MEASURE Evaluation.
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.
The Global Plan to Stop TB, (1)
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Ilesh V. Jani, MD PhD Instituto Nacional de Saúde Maputo, Mozambique.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
Comparison of Molecular and Conventional Methods for Detection of Multidrug-Resistant Tuberculosis in the United States, 2009 to 2011 Mitchell A. Yakrus,
Global Plan to STOP TB: Diagnostics WG Jane Cunningham Medical Officer WHO/TDR/PDE Secretariat STOP TB Diagnostics Working Group.
Johns Hopkins Center for Tuberculosis Research
Tuberculosis Research of INA-RESPOND on Drug-resistant
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Jason Andrews, MD, SM, DTM&H Division of Infectious Diseases Massachusetts General Hospital Harvard Medical School International AIDS Society July 2, 2013.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
The Global Problem of Extensively Drug Resistant TB Peter M. Small, MD Institute for Systems Biology Bill and Melinda Gates Foundation February 17, 2008.
Revision of new diagnostics for TB
Revising the WHO TB Treatment Guidelines Process and new recommendations Malgosia Grzemska Matteo Zignol Stop TB Department World Health Organization DEWG.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
1 [INSERT SPEAKER NAME DATE & LOCATION HERE] Ethics of Tuberculosis Prevention, Care and Control MODULE 7: GAP BETWEEN AVAILABILTY OF DRUG SUSCEPTIBILITY.
Molecular diagnosis of drug resistant tuberculosis by a DNA array
Abstract Modern chemotherapy has played a major role in our control of tuberculosis. Yet tuberculosis still remains a leading infectious disease worldwide.
TB Control Measures: From development and endorsement to adoption and implementation Léopold Blanc TBS Stop TB department WHO Christy Garcia University.
PROF. MADHUKAR PAI, MD, PHD CANADA RESEARCH CHAIR IN TRANSLATIONAL EPIDEMIOLOGY & GLOBAL HEALTH DIRECTOR, MCGILL GLOBAL HEALTH PROGRAMS ASSOCIATE DIRECTOR,
GERIATRIC TUBERCULOSIS: ISSUES Dr. (Prof.)Vijay Kumar Arora Vice Chancellor Ex Director NITRD Delhi,Ex Director-professor JIPMER, Ex Additional DGHS GOI.
Diagnostics - More than 100 years old Drugs – Last drug 40 years old Vaccine – Nearly 90 years old Lucica Ditiu Executive Secretary, Stop TB Partnership.
The Future of Drug-Resistant TB: How Do We Prevent a Nightmare? (HINT: By Treating It!) David Dowdy, MD PhD B. Frank Polk Assistant Professor of Epidemiology.
Patient with Presumptive TB HIV Status PositiveNegative % Empiric Tx of Patients with Active TB % Empiric Tx of TB-Symptomatic Patients without True TB.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
Diagnostic algorithms of TB case finding and their effect on TB epidemiology in Russian Regions Andrey Maryandyshev, Elena Nikishova Northern State Medical.
Global Tuberculosis Control 2007 Did we reach the 2005 targets? Will we achieve the Millennium Development Goals?
Tuberculosis - the opportunity in our lifetime Dr. Lucica Ditiu | Executive Secretary | Stop TB Partnership 09.April.2013 | Brussels, Belgium.
Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.
PMDT IN CHINESE TAIPEI ECONOMY Anita Pei-Chun Chan, MD, PhD Medical Officer, TCDC Associated Director, TB Research Center, TCDC Assistant Professor, Institute.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
Tuberculosis in the United States
TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA
Monitoring and Evaluation Frameworks
Treatment of TB Disease
Copyright © 2006 American Medical Association. All rights reserved.
William Burman Denver Public Health Tuberculosis Trials Consortium
Drug Resistant (DR) TB (Back to Basics)
وضعیت بیماری سل در جهان، منطقه و ایران
Keeping Kids in the Picture: Pediatric TB in the COPs process
اهمیت سل در چیست؟ حدود یک سوم جمعیت جهان(2 میلیارد نفر)با میکروب سل آلوده شده اند سالانه 9 میلیون نفر به سل فعال مبتلا می شوند هر ساله 1/5 تا 2 میلیون.
اهداف جهاني تعيين شده از سوي WHOبراي كشورها
Funding gaps to realize the Global Plan to End TB
Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis  Dr Emily A Kendall, MD, Anthony.
Treatment of Drug Resistant TB - Questions
Synchronization of a basic diagnostic algorithm (linked diagnostic tests) with different levels of diagnostic services. Synchronization of a basic diagnostic.
Basic diagnostic algorithm to link the molecular line probe assay with solid culture- and liquid culture-based growth detection and susceptibility testing.
Procedures (Decision on Diagnosis based on Laboratory Results)
Presentation transcript:

Do we need to test for isoniazid resistance? No conflict of interest Claudia Denkinger, MD PhD McGill University, Montreal Foundation for Innovative New Diagnostics

Context Xpert rapidly being rolled Xpert includes RIF but not INH resistance testing INH resistance is much more common than MDR Treatment of INH resistant MTB with 1 st line drugs is associated with increase failure/relapse rates and increased development of MDR Niemz Exp Rev Mol Diag 2012 Menzies PLOS Med 2009 Jacobson CID 2011 Smith IJTLD 2012

??? Should the next generation of molecular tests include detection of isoniazid resistance to prevent -A further increase in INH resistance -INH resistance driving MDR resistance

Latent TB Infection New active TB - Access to diagnostics Susceptible Treated/Cured Previously treated active TB – Access to diagnostics New active TB – No access to diagnostics Failure Self cure Primary progression Secondary progression Secondary progression Failing on therapy Cured Default/Relaps e Cured Cured with 2 nd line or DST guided treatment Failing on 2 nd line or DST- guided treatment Reinfection

Model Steady state (60 years ago) Rise of MDR and INH over 60 years to levels reported today (2.1%, 15%) for epidemiological setting like India Standard diagnostic, calibrated to CDR (~75%) Molecular testing: 95% sensitivity MDR Rx at baseline only for pts failing 1 st line Rx WHO Global report 2012 EquilibriumYear 0Implementation of tests

Input parameters WHO Global report 2012 Menzies PLOS Med 2009 Jacobson CID 2011

Scenarios with molecular test 1.TB detection only 2.Rif detection 3.INH +RIF detection  Low coverage: 15%, 25%, 30% > new, relapse/default, failure  High coverage: 50%, 80%, 100% > new, relapse/default, failure WHO Global report 2012

A B C D

Sensitivity analysis TB+RIF/INH vs TB+RIF 0.2 0

Conclusions INH testing in addition to rifampin resistance detection does not have a substantial effect – on INH resistance – or MDR-TB Testing for rifampin resistance in contrast has a sizeable effect on MDR – Idealized scenario – Reduction in prevalent (chronic) cases early on – Reduction in time to diagnosis as MDR

Limitations Simplified model Not including HIV limits generalizability Not considering IPT > limited use, unclear impact on resistance Not considering different health sectors Not accounting for possible beneficial effects of detection of rifampin monoresistance Smith IJTLD 2012 Balcells EID 2006 WHO Report 2012 RNTCP 2011

Supplementary Figures

A B C D Figure S1

A B C D Figure S3

Figure S5 A B C D

Thank you! Questions???

Acknowledgement David Dowdy Madhu Pai Dick Menzies